Bioequivalence tests to be stimulated

Published: 2004-05-10 06:58:00

Updated: 2004-05-10 06:58:00

The Korea Food and Drug Administration says that in-house undertakings of bioequivalence tests by pharmaceutical firms will be stimulated by the policy of the administration to conduct its commissioned standard bioequivalence protocol study for the following 15 ingredients in addition to the curr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK